Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3.
A bispecific antibody construct (bAb) recognising CD3 and epidermal growth factor receptor (EGFR) was studied in vitro. Human peripheral blood lymphocytes (PBL), pre-activated with monoclonal antibody OKT-3 or with irradiated tumour cells, were armed with the bAb construct and targeted to autologous and allogeneic tumour target cells in culture. bAb EGFR x CD3 promoted significant cytolysis even at a concentration of 1 ng/ml. The specificity of target cell lysis was provided by the EGFR specificity of the bAb, as tumour cells negative for EGFR were not lysed. However, not only EGFR-positive tumour cells but also EGFR-positive normal cells were killed. Human renal cancer cell lines and the normal autologous kidney cell cultures expressing the same level of EGFR molecules were lysed to a similar extent. These results may contribute toward the planning of future clinical trials with such bAb.
Knuth
A
A
II Medizinische Klinik, Hämatologie/Onkologie, Krankenhaus Nordwest, Frankfurt a. Main, Germany.
Bernhard
H
H
Jäger
E
E
Wölfel
T
T
Karbach
J
J
Jäggle
C
C
Strittmatter
W
W
Meyer zum Büschenfelde
K H
KH
D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014407:Tumor Cells, Cultured
D018033:Antibodies, Bispecific; D017252:CD3 Complex; D066246:ErbB Receptors